Pharmacokinetic-pharmacodynamic modeling to evaluate the relative impact of immune response and meropenem on bacterial killing in vivo
Antimicrobial Agents and Chemotherapy · 01.04.2026 · 70 (4)
DOI: 10.1128/aac.01788-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 01.04.2026. Verfasst von Raphaël Saporta und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Meropenem, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: H2020 Marie Skłodowska-Curie Actions, Swedish Research Council.
Abstract (Originalsprache)
In vivo antibiotic pharmacokinetic-pharmacodynamic (PKPD) properties are typically studied in neutropenic infection models, limiting the understanding of interactions between immune cells and antibiotics. This study aimed to characterize the impact of immune status on meropenem PKPD and dose-response in a mouse lung infection model, and to quantify the relative contribution of immune response and meropenem to bacterial killing. Meropenem PK was analyzed in plasma and epithelial lung fluid, and bacterial counts were monitored over 24 h following 40 or 300 mg/kg meropenem doses every 4 h in a mouse lung infection model with varying immunosuppression levels (neutropenic, intermediate, or immunocompetent). A PKPD model was developed to quantify bacterial killing by the immune response and meropenem over time. Dose-fractionation studies were simulated to investigate meropenem dose-response in different immune states. Observed differences in meropenem concentration-time profiles were explained by a higher volume of distribution in immunocompetent mice. The immune response was described by phagocytosis and digestion processes. The meropenem effect was best quantified based on plasma concentrations, with a maximal killing rate of 0.934 h −1 and EC 50 = 1.62 mg/L. The lower contribution of meropenem to bacterial killing in intermediate and immunocompetent conditions was explained as a lower fraction of bacteria being affected by meropenem. In simulations, the immune status impacted PKPD target derivation. The developed model characterized differences in meropenem PK between neutropenic and immunocompetent in vivo infection models and quantified the contributions of immune response and meropenem to bacterial killing, with a reduced effect of meropenem in immunocompetent systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Uppsala University, Uppsala, Sweden.
- Division of Infectious Diseases, Paul-Ehrlich-Institut, Langen, Germany.
ORCID-Profile: Raphaël Saporta, Aghavni Ginosyan, Irena Loryan, Elisabet I Nielsen, Isabelle Bekeredjian-Ding, Bernhard Kerscher, Lena E Friberg
Förderung
- H2020 Marie Skłodowska-Curie Actions
- Swedish Research Council
Zitieren
APA
Saporta, R., Tassi, N., Biordi, V., Ticha, O., Ginosyan, A., Loryan, I., Nielsen, E. I., Bekeredjian-Ding, I., Kerscher, B., & Friberg, L. E. (2026). Pharmacokinetic-pharmacodynamic modeling to evaluate the relative impact of immune response and meropenem on bacterial killing in vivo. Antimicrobial Agents and Chemotherapy, 70(4). https://doi.org/10.1128/aac.01788-25
Vancouver
Saporta R, Tassi N, Biordi V, Ticha O, Ginosyan A, Loryan I, et al. Pharmacokinetic-pharmacodynamic modeling to evaluate the relative impact of immune response and meropenem on bacterial killing in vivo. Antimicrobial Agents and Chemotherapy. 2026;70(4). doi:10.1128/aac.01788-25
BibTeX
@article{Saporta2026,
author = {Saporta, Raphaël and Tassi, Natália and Biordi, Veronica and Ticha, Olga and Ginosyan, Aghavni and Loryan, Irena and Nielsen, Elisabet I and Bekeredjian-Ding, Isabelle and Kerscher, Bernhard and Friberg, Lena E},
title = {Pharmacokinetic-pharmacodynamic modeling to evaluate the relative impact of immune response and meropenem on bacterial killing in vivo},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {4},
doi = {10.1128/aac.01788-25}
}
EUVIMED